Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 Next >
News headline image
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Provides Update Regarding Annual Meeting
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
From AIM ImmunoTech Inc.
Via Business Wire
Tickers AIM
News headline image
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.